Multicenter phase II study of FOLFIRI and bevacizumab as second-line treatment in advanced or recurrent colorectal cancer.

Trial Profile

Multicenter phase II study of FOLFIRI and bevacizumab as second-line treatment in advanced or recurrent colorectal cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms PROMETEUS-II
  • Sponsors Yakult Honsha
  • Most Recent Events

    • 02 Apr 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top